Post by thekindaguyiyam on Apr 14, 2014 23:49:28 GMT -5
translate.google.com/#auto/en/2014年全球胰岛素市场目前规模浅析%0A作者：中研网来源：中研网2014-4-15%209%3A58%3A58%0A关键词：%20胰岛素%20Mannkind%20市场%20分析%0A%0A%0A%0A过去的一周时间，美股各板块集体大跌，板块平均跌幅逾2%25。市值上千万的个股中仅有12只涨幅过20%25。其中口服胰岛素药物生产厂商MannkindCorp以62.69%25的周涨幅位列第一。%0A%0AMannkind上周宣布，历经13年的漫长研究，公司的口服胰岛素产品Afrezza于4月1日获得美国药监局顾问小组推荐批准上市，这将是美国药监局批准的首个口服胰岛素产品。美国药监局称这款药物将会帮助那些对胰岛素注射针头有恐惧心理的患者治疗糖尿病。%0A%0A因为被指控隐瞒旗下糖尿病药物艾可拓（Actos）相关致癌风险，日本最大制药商武田制药被美国联邦法院判处60亿美元的天价罚款。而武田的合作推广方美国礼来制药则被判罚30亿美元的罚款。艾可拓是治疗二型糖尿病用药，在国内外市场均拥有极高的市场占有率。本次艾可拓被重罚，对于口服胰岛素类产品打开了全新的市场空间。%0A%0A据上证报报道，去年12月，在美上市的以色列医药公司Oramed医药曾宣布，该公司的独家新药，口服胰岛素ORMD-0801二期临床测试成功，在欧洲获得了专利获批，将被允许在欧洲以及承认欧洲药监局条例的主要国家作为一型糖尿病的治疗药物使用。公司股价五个交易日累计涨幅达115.83%25。%0A%0A全球胰岛素市场目前规模大约为140亿美元，中国已是世界上糖尿病第二大高发国，患者超过1亿人。因此口服胰岛素在我国同样拥有巨大市场空间。通化东宝上月底曾公告，公司与美国DANCE生物制药有限公司签署了重组人胰岛素原料药供货协议，用于（吸入式）口服胰岛素产品全球三期临床和商业销售。公司重组人胰岛素原料药去年也通过了欧盟的产品认证，2013年公司人胰岛素原料药出口同比增长60%25以上。亚宝药业曾与中科院生物物理所签署了“中科亚宝蛋白质与多肽药物工程研究中心”共建协议，合作开发口服胰岛素系列产品，为时已有四年。(生物谷Bioon.com)
2014 Scale of global insulin market is currently
Author : Central Research Network Source: Research Network 2014-4-15 9:58:58
Keywords : Insulin Mannkind Market Analysis
Last week, U.S. stocks fell for each sector collective , sector average fell more than 2%. The market value of tens of millions , only 12 stocks rose over 20%. Which oral insulin medication manufacturers MannkindCorp weekly gain to 62.69% ranked first .
Mannkind announced last week , after 13 long years of research , the company's oral insulin product Afrezza on April 1 by the U.S. Food and Drug Administration advisory panel recommended approval of the listing , it will be the United States Food and Drug Administration approved the first oral insulin products. The U.S. Food and Drug Administration said the drug will help patients who have a fear of needles insulin treatment of diabetes .
Because they were accused of concealing the cancer risk associated diabetes drug Actos 's (Actos), Japan's largest drugmaker Takeda Pharmaceutical was sentenced to a fine of $ 6,000,000,000 astronomical U.S. federal courts. And Takeda 's Cooperative Extension in Active- Eli Lilly were fined $ 3 billion in fines . Actos is the treatment of Type II diabetes medication, both in the domestic and international markets with a high market share. The Actos heavy penalties , for oral insulin products open up new market space.
Zhengbao According to reports, last December , the Israeli pharmaceutical companies listed in the U.S. Oramed Pharmaceutical has announced that the company 's exclusive drug , oral insulin ORMD-0801 Phase II clinical testing success , received a patent granted in Europe , will be allowed in Europe and the major European countries recognize the Food and Drug Administration regulations used as a type of diabetes therapy . Company's share price five trading days , the cumulative increase of 115.83% .
Global insulin market is currently about $ 14 billion scale , China has the world's second largest high incidence of diabetes patients over 100 million people . Therefore, in our oral insulin also has a huge market space. Tonghua Dongbao announcement late last month , the company Bio- Pharmaceutical Co., Ltd. and the United States signed DANCE recombinant human insulin pharmaceutical raw materials supply agreement for ( inhaled ) oral insulin products worldwide Phase III clinical and commercial sales. Recombinant human insulin APIs company last year by the EU's product certification, in 2013 the company human insulin pharmaceutical raw materials exports grew more than 60% . Ya Bao Pharmaceutical worked with the Institute of Biophysics signed the " treasure of protein and peptide drugs Keya Engineering Research Center " Building an agreement to develop oral insulin products, last four years . ( Bio Valley Bioon.com)
Google
2014 Scale of global insulin market is currently
Author : Central Research Network Source: Research Network 2014-4-15 9:58:58
Keywords : Insulin Mannkind Market Analysis
Last week, U.S. stocks fell for each sector collective , sector average fell more than 2%. The market value of tens of millions , only 12 stocks rose over 20%. Which oral insulin medication manufacturers MannkindCorp weekly gain to 62.69% ranked first .
Mannkind announced last week , after 13 long years of research , the company's oral insulin product Afrezza on April 1 by the U.S. Food and Drug Administration advisory panel recommended approval of the listing , it will be the United States Food and Drug Administration approved the first oral insulin products. The U.S. Food and Drug Administration said the drug will help patients who have a fear of needles insulin treatment of diabetes .
Because they were accused of concealing the cancer risk associated diabetes drug Actos 's (Actos), Japan's largest drugmaker Takeda Pharmaceutical was sentenced to a fine of $ 6,000,000,000 astronomical U.S. federal courts. And Takeda 's Cooperative Extension in Active- Eli Lilly were fined $ 3 billion in fines . Actos is the treatment of Type II diabetes medication, both in the domestic and international markets with a high market share. The Actos heavy penalties , for oral insulin products open up new market space.
Zhengbao According to reports, last December , the Israeli pharmaceutical companies listed in the U.S. Oramed Pharmaceutical has announced that the company 's exclusive drug , oral insulin ORMD-0801 Phase II clinical testing success , received a patent granted in Europe , will be allowed in Europe and the major European countries recognize the Food and Drug Administration regulations used as a type of diabetes therapy . Company's share price five trading days , the cumulative increase of 115.83% .
Global insulin market is currently about $ 14 billion scale , China has the world's second largest high incidence of diabetes patients over 100 million people . Therefore, in our oral insulin also has a huge market space. Tonghua Dongbao announcement late last month , the company Bio- Pharmaceutical Co., Ltd. and the United States signed DANCE recombinant human insulin pharmaceutical raw materials supply agreement for ( inhaled ) oral insulin products worldwide Phase III clinical and commercial sales. Recombinant human insulin APIs company last year by the EU's product certification, in 2013 the company human insulin pharmaceutical raw materials exports grew more than 60% . Ya Bao Pharmaceutical worked with the Institute of Biophysics signed the " treasure of protein and peptide drugs Keya Engineering Research Center " Building an agreement to develop oral insulin products, last four years . ( Bio Valley Bioon.com)
